Sai Life Sciences announced its financial results for FY 2025-26, reporting a significant increase in performance. Total income grew by 29.5% year-on-year to ₹2,192 crore, while profit after tax (PAT) saw a substantial rise of 105.3% YoY to ₹349 crore. This robust growth reflects strong execution across the business and careful management of costs, bolstered by strategic investments made over recent years.
Sai Life Sciences Reports Strong Financial Performance for FY 2025-26
Sai Life Sciences Limited has announced its financial results for the fiscal year 2025-26, highlighting a year of strong growth and improved profitability. The company’s total income increased by 29.5% year-on-year, reaching ₹2,192 crore, up from ₹1,731 crore in the previous year. This growth has been attributed to robust demand across both its Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) segments, underpinned by consistent execution and increasing traction across the company’s integrated service offerings.
Key Financial Highlights:
- Profit After Tax (PAT): Increased by 105.3% year-on-year to ₹349 crore, with the PAT margin improving to 15.9% from 10.0% in the prior year.
- EBITDA: Showed a significant increase of 55.6% year-on-year, reaching ₹661 crore from ₹425 crore in FY 2024-25. The EBITDA margin expanded by 508 basis points to 30.1%.
- Capital Expenditure: The company incurred ₹633 crore of capital expenditure during FY 2025-26 and announced a planned program of ₹1,100–1,300 crore for FY 2026-27, focusing on capacity expansion, capability enhancement, and AI and technology investments.
These financial highlights indicate strong operational execution and the benefits derived from strategic investments made over the past several years, positioning the company for continued growth and enhanced capabilities.
Source: BSE
